• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Newbury Pharmaceuticals

2.40 SEK+14.29 %9/7 17:29
Less than 1K followers

NEWBRY

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+14.29 %
+28.69 %
+100.00 %
+103.39 %
+108.70 %
-21.05 %
-24.29 %
-
-80.95 %

Newbury Pharmaceuticals is a pharmaceutical company. The company develops a pipeline of in-house developed and licensed products with a focus on specialty drugs in areas such as oncology, rare diseases, and neurology. The company conducts its business within the Scandinavian market. Newbury Pharmaceuticals was founded in 2020 and has its headquarters in Lund.

Read more
Market cap
72.95M SEK
Turnover
222.81K SEK
Revenue
31.58M
EBIT %
-69.57 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28/10
2026

Annual report '26

20/1
2027

General meeting '27

20/1
2027

Interim report Q1'27

Regulatory press release2026-07-08 08:00

Newbury Pharmaceuticals interim report September 2025 – May 2026

Newbury Pharmaceuticals
Press release2026-04-17 10:00

Newbury Pharmaceuticals Secures Generic Approval for Palbociclib Newbury

Newbury Pharmaceuticals
Regulatory press release2026-04-15 10:30

Extraordinary General Meeting of Newbury Pharmaceuticals AB

Newbury Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-04-15 08:00

Newbury Pharmaceuticals interim report September 2025 – February 2026

Newbury Pharmaceuticals
Regulatory press release2026-03-26 19:30

Kallelse till extra bolagsstämma i Newbury Pharmaceuticals AB

Newbury Pharmaceuticals
Regulatory press release2026-03-26 14:00

Newbury Pharmaceuticals extends and increases loan agreement to SEK 30m, convenes EGM

Newbury Pharmaceuticals
Intervju med Newbury Pharmaceuticals VD under SCF:s 17:e Kapitalmarknadsdag Life Science6:14
Video2026-03-19 08:07 by
Pia Maljanen

Intervju med Newbury Pharmaceuticals VD under SCF:s 17:e Kapitalmarknadsdag Life Science

Newbury Pharmaceuticals presenterade vid Stockholm Corporate Finance 17:e kapitalmarknadsdagar Life Science 2026.

Newbury Pharmaceuticals
Press release2026-03-18 16:45

Newbury Pharmaceuticals has entered into a new partnership for Prucalopride tablets

Newbury Pharmaceuticals
Newbury Pharmaceuticals AB, Investor Day, Stockholm Corporate Finance Life Science Seminarium 2026
Webcast2026-03-17 12:00

Newbury Pharmaceuticals AB, Investor Day, Stockholm Corporate Finance Life Science Seminarium 2026

Newbury Pharmaceuticals
Stockholm Corporate Finance 17:e Kapitalmarknadsdagar — Life Science 2026 │ 17:e mars
Webcast2026-03-17 08:00

Stockholm Corporate Finance 17:e Kapitalmarknadsdagar — Life Science 2026 │ 17:e mars

Välkommen att lyssna på Stockholm Corporate Finance 17:e Kapitalmarknadsdagar — Life Science 2026 │ 17:e mars.

OncopeptidesIntervaccAcuCortOrexoOncoZengeNewbury Pharmaceuticals
Press release2026-01-29 12:00

Newbury Pharmaceuticals Secures 12-Month Pazopanib Tender in Denmark

Newbury Pharmaceuticals
Regulatory press release2026-01-21 08:00

Newbury Pharmaceuticals interim report September 2025 – November 2025

Newbury Pharmaceuticals
Regulatory press release2026-01-14 11:15

ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB

Newbury Pharmaceuticals
Regulatory press release2025-12-10 20:30

Newbury Pharmaceuticals publishes its annual report for 2024/2025

Newbury Pharmaceuticals
Regulatory press release2025-12-09 16:15

Kallelse till årsstämma i Newbury Pharmaceuticals AB

Newbury Pharmaceuticals
Press release2025-11-18 13:50

Nordic Market Update

Newbury Pharmaceuticals
Regulatory press release2025-11-11 13:15

Newbury Pharmaceuticals appoints its founder Karl Karlsson as new CEO

Newbury Pharmaceuticals
Regulatory press release2025-10-29 08:00

Newbury Pharmaceuticals year-end report September 2024 – August 2025

Newbury Pharmaceuticals
Press release2025-10-24 08:30

Newbury Pharmaceuticals Secures Generic Approval for Mirtazapin Newbury

Newbury Pharmaceuticals
Press release2025-10-23 14:30

Newbury Pharmaceuticals Secures Generic Approval for Ivermectin Newbury

Newbury Pharmaceuticals